☆ 4.7 Article

Effect of tofacitinib on clinical and laboratory findings in severe and resistant patients with COVID-19

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Immunology

Role of the humoral immune response during COVID-19: guilty or not guilty?

Melyssa Yaugel-Novoa et al.

Summary: Systemic and mucosal humoral immune responses play a crucial role in fighting the respiratory viral infection caused by the SARS-CoV-2 virus. Patient characteristics and disease severity can affect the dynamics of antibody infections, with higher antibody levels observed in severe cases. Vaccines have shown limited efficacy against new viral variants.

MUCOSAL IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Use of disease-modifying drugs(tocilizumab, tofacitinib, and baricitinib-a biological or synthetic target specific) in patients hospitalized with COVID-19

Alexandre Naime Barbosa et al.

Summary: The Guidelines Project is an initiative aimed at standardizing doctor's conduct and assisting in decision-making. Physicians must critically evaluate the information provided by this project and make decisions based on patients' conditions.

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA (2022)

Add to Collection

Review Infectious Diseases

JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

Lucas Walz et al.

Summary: The study reviewed the use of Janus kinase-inhibitors and Type I interferons as potential antiviral candidates for COVID-19 patients, showing that patients treated with these drugs had significantly improved clinical outcomes. While the results are promising, further well-conducted randomized controlled trials are needed to confirm the findings.

BMC INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Medicine, General & Internal

JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy

Sairaj Satarker et al.

Summary: As the incidence of COVID-19 increases, efforts are being made to develop therapeutic strategies to combat disease progression, with a focus on the JAK/STAT pathway and its influence on inflammation. Structural and non-structural proteins of SARS-CoV-2 trigger inflammation via this pathway, leading to a cytokine storm in the host. JAK/STAT inhibitors have been employed to reduce excessive inflammation, although their molecular mechanism of action and potential adverse effects require further investigation.

POSTGRADUATE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Patricia O. Guimaraes et al.

Summary: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. The mortality rate was lower in the tofacitinib group within 28 days. However, the rate of serious adverse events was similar in both groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19

Roman Maslennikov et al.

Summary: This study aimed to evaluate the efficacy and safety of tofacitinib in managing cytokine release syndrome in COVID-19. Results showed lower mortality and intensive care unit admission rates in the tofacitinib group compared to the control group, with improvements in lung volume, oxygen saturation, and CRP levels in the tofacitinib group.

PULMONARY PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Review Immunology

Immunology of COVID-19: Current State of the Science

Nicolas Vabret et al.

IMMUNITY (2020)

Add to Collection

Editorial Material Immunology

COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome

Toshio Hirano et al.

IMMUNITY (2020)

Add to Collection

Article Allergy

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Yang Cao et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19 Definition and Evaluation

Mathias Prokop et al.

RADIOLOGY (2020)

Add to Collection

Editorial Material Multidisciplinary Sciences

Cytokine release syndrome in severe COVID-19

John B. Moore et al.

SCIENCE (2020)

Add to Collection

Letter Medicine, General & Internal

COVID-19: consider cytokine storm syndromes and immunosuppression

Puja Mehta et al.

LANCET (2020)

Add to Collection

Review Immunology

Immunomodulatory Drugs in the Management of SARS-CoV-2

Daniel R. Burrage et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Allergy

Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19

De Chang et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Review Cell Biology

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

Jin Wang et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2020)

Add to Collection

Review Rheumatology

Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review

Y. C. Tsai et al.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The regulation of JAKs in cytokine signaling and its breakdown in disease

Henrik M. Hammaren et al.

CYTOKINE (2019)

Add to Collection

Review Cell Biology

Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs

Massimo Gadina et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2018)

Add to Collection

Article Medical Laboratory Technology

JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa

Patrick P. C. Boor et al.

TRANSLATIONAL RESEARCH (2017)

Add to Collection

Review Pharmacology & Pharmacy

Tofacitinib: A Review in Rheumatoid Arthritis

Sohita Dhillon

DRUGS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

Apostolos Kontzias et al.

CURRENT OPINION IN PHARMACOLOGY (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.